黑料网

Abstract

This pharmacokinetic study aimed to determine the systemic bioavailability of intranasal fluticasone, a widely used corticosteroid for the treatment of allergic rhinitis. The study employed a randomized, double-blind, crossover design involving healthy volunteers. Each participant received intranasal fluticasone or a placebo in a random sequence on separate occasions. Blood samples were collected at predetermined intervals post-administration to quantify plasma fluticasone concentrations. The results demonstrated a rapid absorption of intranasal fluticasone, with a Tmax (time to reach maximum concentration) of X hours. The mean Cmax (maximum plasma concentration) of fluticasone was found to be Y ng/mL. The systemic exposure, as measured by the area under the concentrationtime curve (AUC), was Z ng*h/mL. These values were significantly higher than those observed in the placebo group, confirming the systemic absorption of intranasal fluticasone. Furthermore, the study assessed the safety profile of intranasal fluticasone, revealing no significant adverse events during the observation period. The data collected suggests that intranasal fluticasone is well-tolerated and does not pose substantial systemic exposurerelated risks. In conclusion, this pharmacokinetic study provides valuable insights into the systemic bioavailability of intranasal fluticasone, contributing to a better understanding of its pharmacological behavior. The findings support the clinical use of intranasal fluticasone for the management of allergic rhinitis, while also highlighting the importance of monitoring potential systemic effects in long-term treatment scenarios. Further investigations may explore the relationship between systemic exposure and therapeutic efficacy in a clinical setting.